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Background:  Syncope  is  one  of the most  common  reasons  for emergency  department  and  urgent  care
clinic visits.  The  management  of  syncope  continues  to be a challenging  problem  for front-line  providers
inasmuch  as  there  are  a  multitude  of  possible  causes  for syncope  ranging  from  relatively  benign  conditions
to  potentially  life-threatening  ones.  In  any  event,  it is  important  to identify  those  syncope  patients  who
are  at immediate  risk  of  life-threatening  events;  these  individuals  require  prompt  hospitalization  and
thorough  evaluation.  Conversely,  it is  equally  important  to avoid  unnecessary  hospitalization  of  low-risk
patients  since  unneeded  hospital  care  adds  to the  healthcare  cost  burden.
Results:  Historically,  front-line  providers  have  taken  a  conservative  approach  with  admission  rates  as  high
as 30–50%  among  syncope  patients.  A number  of  studies  evaluating  both  the  short-  and long-term  risk
of  adverse  events  in  patients  with  syncope  have  focused  on  development  of risk-stratiﬁcation  guidelines
to  assist  providers  in  making  a  conﬁdent  and  well-informed  choice  between  hospitalization  and  out-
patient  referral.  In this  regard,  a much  needed  consensus  on  optimal  decision-making  process  has  not
been  developed  to  date.  However,  knowledge  from  various  available  risk-stratiﬁcation  studies  can  be
helpful.
Conclusion:  This  review  summarizes  the  ﬁndings  of various  risk-stratiﬁcation  studies  and  points  out
key  differences  between  them.  While,  the existing  risk-stratiﬁcation  methods  cannot  replace  critical
assessment  by  an  experienced  physician,  they  do provide  valuable  guidance.  In  addition,  the  various
risk-assessment  schemes  highlight  the  need  for  careful  initial  clinical  assessment  of syncope  patients,
selective  testing,  and  being  mindful  of the  short-  and  long-term  risks.
©  2014  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
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Table 1
The diagnostic classiﬁcation of the causes of syncope modiﬁed from the European
Society of Cardiology syncope practice guidelines.
Reﬂex (neurally-mediated) syncope
Vasovagal:
-  triggered by emotional distress
-  triggered by orthostatic stress
Situational:
-  cough, sneeze
- gastrointestinal stimulation
-  micturition
- others
Carotid sinus syncope
Orthostatic hypotension syncope
Volume depletion:
- inadequate ﬂuid intake (hot weather), diarrhea, vomiting, etc.
Drug-induced orthostatic hypotension:
- alcohol, vasodilators, diuretics, beta-adrenergic blockers
Primary autonomic failure:
- pure autonomic failure, multiple system atrophy, Parkinson’s disease with
autonomic failure, Lewy body dementia
Secondary autonomic failure:
- diabetes, amyloidosis, spinal cord injuries
Cardiac syncope (cardiovascular)
Arrhythmia as primary cause:
Bradycardia:
- sinus node dysfunction, atrioventricular conduction system disease
-  implanted device malfunction
Tachycardia:
- supraventricular including atrial ﬁbrillation
- ventricular (idiopathic secondary to structural heart disease, or due to
channelopathies)
Structural disease:
- Cardiac: cardiac valvular disease, acute myocardial infarction/ischemia,
hypertrophic cardiomyopathy, cardiac masses (atrial myxoma, tumors, etc.),
pericardial disease/tamponade, congenital anomalies of coronary arteries,
prosthetic valves dysfunction72 V.K. Puppala et al. / Journal 
ntroduction
Syncope is a syndrome characterized by a transient self-limited
pisode of loss of consciousness occurring as a result of a brief inter-
uption of oxygen supply to the brain. This interruption of cerebral
utrient ﬂow in a syncopal event is almost always due to transient
essation of blood ﬂow [1,2]. A transient reversible drop in sys-
emic arterial blood pressure to a level below that needed to sustain
erebral perfusion is the most common cause of syncope. Other
ossibilities are rare, and include acute hypoxemia (e.g. aircraft
ecompression) or major metabolic disturbance affecting neuronal
athways.
Since transient global cerebral hypoperfusion is the sine qua non
f syncope pathophysiology, other causes of loss of consciousness
hould not be classiﬁed as ‘syncope’. Thus seizures, concussions,
ypoglycemia, and other non-perfusion related disturbances are
eparate diagnostic issues; these are non-syncope causes of tran-
ient loss of consciousness (TLOC) [1,3].
In true syncope, the episode is characterized by a rapid onset
f loss of consciousness with or without any warning symptoms.
ven when warning symptoms are present before syncope, loss of
onsciousness usually occurs within 10–20 s of their onset. Recov-
ry is typically prompt and complete without any need for medical
ntervention and without any new residual neurologic ﬁndings.
lassiﬁcation of syncope
The classiﬁcation of syncope is mainly based on the underlying
echanisms that lead to the ﬁnal event of transient global hypo-
erfusion. The diagnostic classiﬁcation of the causes of syncope
odiﬁed from the European Society of Cardiology (ESC) syncope
ractice guidelines [1] is summarized in Table 1.
eurally-mediated syncope (also termed neural reﬂex syncope)
This type of syncope includes a number of conditions. The most
mportant and also the most common within this category is vaso-
agal syncope. The second most common is carotid sinus syncope
CSS) which mostly occurs in the elderly and primarily in men  [3–6].
arotid sinus hypersensitivity (CSH) is a clinical ﬁnding elicited by
assaging the carotid sinus. CSH should be distinguished from CSS
s the former is a clinical ﬁnding and the latter is a clinical mani-
estation. CSS is only diagnosed if carotid massage causes sufﬁcient
radycardia (usually >6 s) and/or hypotension to cause reproduc-
ion of the patients’ symptoms.
Situational syncope is a third category of reﬂex faint; it includes
yncope triggered by any of a number of activities such as: mic-
urition, defecation, coughing, or swallowing. The initial event (e.g.
icturition) triggers [1,3] either a slow heart rate or depressed
ascular tone (or both) that results in sufﬁcient hypotension to
ause transient cerebral hypoperfusion and ultimate transient self-
imited episode of loss of consciousness. In some cases (e.g. cough
yncope, trumpet-blowers syncope), transient venous obstruction
ue to increased intra-thoracic pressure may  contribute to cerebral
ypoperfusion.
rthostatic hypotension
Orthostatic syncope occurs as result of the body’s inability to
aintain blood pressure adequate for cerebral perfusion when the
ndividual moves to the upright posture, and which in turn results
n TLOC [1,7,8]. The change in posture from lying down to an upright
osition results in shift of as much as 500–1000 mL  of blood away
rom the chest to venous capacitance system below the diaphragm;
his shift in turn results in diminished venous return to heart and-  Other cardiovascular: pulmonary embolus/hypertension, acute aortic
dissection
consequent reduction of cardiac ﬁlling pressure and stroke volume
leading to hypotension and cerebral hypoperfusion.
The human body has physiological defenses against orthostatic
hypotensive episodes. These include a reﬂex increase in heart
rate, reﬂex arterial and venous vasoconstriction (especially in the
splanchnic bed and lower extremities), and neuroendocrine adjust-
ments (activation of renin–angiotensin–aldosterone system) [7].
All of these defenses prevent healthy individuals from having a syn-
copal event. However, in certain situations these defenses could be
undermined. For example, superimposed volume depletion or loss
of impaired cardiac response due to chronotropic incompetence, or
impaired reﬂex vasoconstriction due to autonomic dysfunction or
medications (e.g. beta-blockers, etc.), or loss of skeletal muscle tone
which is common in the elderly, may  cause reduced venous return.
The individual as a result of syncope will slump to gravitationally
neutral position which usually results in prompt resumption of
cerebral perfusion. Physical counter pressure maneuvers such as
leg-crossing and muscle straining have been found to be helpful
in increasing venous return by enhancing muscle pump activity
[1].
Syncope due to cardiac arrhythmias
Cerebral hypoperfusion resulting in syncope can occur due to
either brady- or tachy-arrhythmias. Bradycardia is the more com-
mon; in this category, symptomatic hypotension can occur as a
result of sinus pauses, high-grade atrioventricular block or asystole
that occurs at the termination of an atrial arrhythmia (particularly
at the end of an episode of atrial ﬁbrillation). Cardiac pacemaker
placement is helpful in preventing these bradycardiac episodes.
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patient who  presents with TLOC/collapse based on the ESC Syncope
Task Force Guidelines [1].
At the present time, despite tutoring the physicians in ESC guide-
lines, high admission rates appear to persist (as high as 30–50% perV.K. Puppala et al. / Journal 
Both supraventricular and ventricular tachyarrhythmias may  be
esponsible for triggering syncope. Neurally-mediated hypotension
ay  also contribute in these patients. Patients with autonomic dys-
unction are at greatest risk for arrhythmia-related syncope since
rotective reﬂexes that are supposed to be in effect to counter the
achycardic stress are absent or are too sluggish.
The occurrence of syncope due to ventricular tachyarrhyth-
ias in patients with poor left ventricular function or due to
hannelopathy (i.e. long QT syndrome, catecholaminergic parox-
smal ventricular tachycardia, Brugada syndrome) is predictive
f increased risk of mortality due to sudden cardiac death [9].
herefore, these patients when identiﬁed need to be promptly
eferred to cardiac electrophysiology for further evaluation; most
ill warrant placement of an implantable cardioverter deﬁbrilla-
or (ICD) and some may  be candidates for mapping and ablation
herapy.
yncope due to structural cardiac disease
Although infrequent, syncope can occur as a result of acute
yocardial infarction or pulmonary embolism. Reduced stroke vol-
me  is the underlying mechanism for cerebral hypoperfusion in
hese cases, although neural-reﬂex factors may  contribute, espe-
ially in the case of acute myocardial ischemia. Valvular/structural
eart disease (e.g. severe aortic stenosis, severe mitral stenosis,
nd large left atrial myxoma) can cause syncope. The cerebral
ypoperfusion in these situations is often a result of the direct
emodynamic impact of an anatomical anomaly as well as neurally-
ediated reﬂexes or lack of them. In patients with severe aortic
tenosis, inappropriate vasodilatation with exertion is an accepted
asis for symptomatic hypotension resulting in syncope [10].
yncope secondary to cerebrovascular causes
The brain is well protected with multiple blood vessels feed-
ng the Circle of Willis and therefore true syncope almost never
ccurs as a direct result of cerebrovascular disease alone. However,
lthough rare, a transient ischemic attack in the vertebrobasilar dis-
ribution may  cause syncope. The presence of posterior circulation
ymptoms such as loss of balance and vertigo makes these events
istinguishable from other causes of syncope.
Steal syndrome associated with subclavian stenosis is another
are condition that can result in symptoms of syncope, dizziness,
ertigo, or nystagmus especially with vigorous use of ipsilateral
rm muscles. Syncope as a solitary manifestation of this condition
s extremely rare [11].
yncope mimics
TLOC can occur in a variety of situations such as seizures, concus-
ions, or intoxication. However, as noted earlier, these are not true
yncopal events as the basis is not cerebral hypoperfusion. They
re being mentioned here due to the diagnostic confusion that they
ay  cause.
Psychogenic pseudosyncope (often termed pseudoseizure by
eurologists especially if jerky muscle movements accompany the
ollapse) is the most common condition in the syncope mimics cat-
gory. It may  be difﬁcult to distinguish these ‘pseudo’ episodes from
rue syncope. However, pseuodosyncope/pseudoseizures most
ften will occur several times a day which almost never happens
n the case of true syncope. Tilt-table testing may  be helpful not
nly in identifying these patients, but also may  permit discussing
he diagnosis frankly with these patients [12].
TLOC can also occur in cases of cataplexy and certain types
f akinetic or minimally kinetic seizures [13]. In elderly people,diology 63 (2014) 171–177 173
accidental falls may  cause TLOC due to concussion. The diagnostic
confusion caused by the above-mentioned conditions can be
cleared by careful attention to history taking, but an experienced
clinician is usually essential. When uncertainty persists, the place-
ment of external or implantable loop recorders may  be helpful to
distinguish these conditions from true syncope.
Risk stratiﬁcation of syncope
Syncope is a challenging symptom for the ﬁrst contact provider
[usually an emergency department (ED) or urgent care physician]
to deal with. First, the patient has usually recovered, so there are no
clear physical ﬁndings to suggest a cause. Second, there are so many
possible causes to consider. Third, the patient or witnesses (if any)
may  have been so surprised by the unexpected event, that detailed
historical ﬁndings are not clearly recollected. Finally, the time
available in an ED to undertake a detailed assessment is limited.
Syncope is not typically a life-threatening condition by itself
(although the underlying cause may  be). However, syncope may
result in untoward consequences such as physical injury and dimin-
ished quality of life. Syncope may  also be an indicator of potentially
life-threatening underlying conditions; for instance, severe struc-
tural heart disease with consequent malignant arrhythmias and
heart failure.
A conﬁdent diagnosis of the cause of a syncope event may  or
may  not be made in ED or clinic. In cases where the cause of TLOC
is established with certainty during initial evaluation, the subse-
quent course of action is clear. However, more often the diagnosis is
unclear and the responsible providers are faced with the dilemma of
choosing between immediate hospitalization versus timely outpa-
tient evaluation. Physicians historically have favored a conservative
course of action resulting in many more patients being admitted to
hospital than is warranted.
The ESC Syncope Task Force provided guidelines for front-
line providers to use for assessing patients presenting with
TLOC/collapse/syncope and thereby arrive at a decision between
inpatient versus outpatient evaluation.
Fig. 1 provides an overview of an approach to assessment of aFig. 1. Flowchart for diagnostic evaluation of patients who  present to the emergency
department (ED) or clinic with transient loss of consciousness (TLOC)/syncope.
Modiﬁed after Ref. [1].
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arious reports). By way of example, Bartoletti et al. [14] examined
dmission rates among patients referred to ED with syncope. The
tudy was based on ESC guidelines for management of syncope [1].
 total of 1124 patients were evaluated and 400 (39.1%) of them
et  at least one criterion for admission per ESC guidelines and 680
60.9%) did not meet any criteria. The actual admission rates were
9.3% among patients with indication and 25.3% among those with-
ut any indication. The high admission rates among the low-risk
atients are indicative of physician concern for patient safety after
ischarge. Similar ﬁndings were noted in EGSYS 2 study [15] where
he admission rate was noted to be as high as 39% despite providing
xpert online assistance to the front-line physicians. The unneces-
ary inpatient admission of low-risk patients not only adds to the
ost of care but also may  not improve patient safety or diagnostic
utcomes.
Risk stratiﬁcation of TLOC/syncope patients has been the sub-
ect of several recent trials with the objective being able to derive
ffective criteria to help choose between inpatient admission and
utpatient syncope clinic referral [16]. The most important objec-
ives of risk-stratiﬁcation studies are to assess the immediate or
hort-term (1 week to 1 month) and longer-term (approximately 1
ear) risk of:
) Death or life-threatening events.
) Recurrence of syncopal events, which in turn may  lead to phys-
ical injury, disability, or diminished quality of life.
Although a consensus risk-stratiﬁcation tool is not yet available,
uch a tool-set would hopefully help ED or clinic physicians deter-
ine the immediate risk of adverse events and if risk is deemed to
e high, it should prompt the physician to admit to the hospital for
urther evaluation [16]. In cases where the risk is felt to be inter-
ediate, one should consider placement of the patient in a syncope
bservation unit if available, as was done in the SEEDS study [17].
n the absence of immediate or short-term risk based on such a
ool, the patients may  be referred for outpatient evaluation prefer-
bly in a clinic dedicated for evaluation of patients with syncope or
LOC. In some situations, the presence of risk factors for increased
ong-term risk of life-threatening events, patients may  need hospi-
alization for further assessment. Several clinical studies focus on
ssessment of short-term and long-term risk factors to provide the
eeded guidance.
hort-term or immediate risk
The short-term or immediate risk of adverse events in the subse-
uent 30 days after initial presentation has been the focus of several
linical studies (Table 2). The ﬁndings are summarized brieﬂy here
nd in Table 2.
) San Francisco rule
The risk factors identiﬁed to be predictive of increased risk of
adverse events within the 7 days included [18]:
1) An abnormal electrocardiogram (ECG) (i.e. new rhythm
changes or non-sinus rhythm).
able 2
hort-term risk (1 week to 1 month).
Study Clinical markers
San Francisco [18] Abnormal ECG, low blood pressure, CHF, SOB,
hematocrit <30%
Rose rule [19] Abnormal ECG, elevated BNP, chest pain, fecal blood
STePS [21] Abnormal ECG, trauma, no warning, male gender
CG, echocardiography; CHF, congestive heart failure; SOB, shortness of breath; BNP,
rain natriuretic peptide.diology 63 (2014) 171–177
2) Systolic blood pressure <90 mmHg.
3) Hematocrit <30%.
4) Congestive heart failure (CHF) (either present at the time of
initial presentation or a history of CHF).
The adverse events included the occurrence of death, myocar-
dial infarction, malignant arrhythmia, pulmonary embolism,
stroke, subarachnoid hemorrhage, signiﬁcant hemorrhage or
other serious events which required return to ED and subse-
quent hospitalization.
2) The Rose rule
This was  an ED-based single center study from Edinburgh
UK that was  designed to identify the risk factors predictive
of an adverse event within 1-month after initial presentation
to ED with syncope [19]. The adverse events were deﬁned
as the occurrence of death, acute myocardial infarction, life-
threatening arrhythmia, being diagnosed with any arrhythmia
which required implantation of a cardiac pacemaker or deﬁbril-
lator within one month, pulmonary embolism, cerebrovascular
accident, hemorrhage or profound anemia requiring blood
transfusion, and any returns to ED within one month which
required urgent surgical or endoscopic intervention. The ﬁnd-
ings that predicted the likelihood of above-mentioned adverse
outcomes included:
1) Brain natriuretic peptide >300 pg/mL.
2) Stool positive for occult blood.
3) Oxygen saturation <94% on room air on initial presentation.
4) Hemoglobin <90 g/L.
5) Chest pain at the time of syncope.
6) Bradycardia (heart rate <50 beats per minute).
Of the study population, 7.1% met  with an endpoint at the end
of one month. The sensitivity and speciﬁcity of Rose rule were
estimated to be 87.2% and 65.5%, respectively.
3) The Boston study
This study included a total of 293 patients who  were followed
for 30 days after their initial presentation to ED with syncope,
looking for occurrence of adverse outcomes such as death, seri-
ous illness that required hospitalization or acute interventions
[20].
Sixty-eight (23%) patients met  with an adverse outcome. The
risk factors identiﬁed in this study that predicted the likelihood
of an adverse event included the following:
1) Acute coronary syndrome (ACS).
2) Conduction system disease.
3) History of cardiac disease.
4) Valvular heart disease.
5) Family history of sudden death.
6) Abnormal vital signs in ED.
7) Volume depletion.
8) Primary central nervous system event.
The sensitivity and speciﬁcity of this study are 97% and 62%,
respectively.
4) STePS study
A total of 676 patients were included in this study after
screening a total of 2700 patients with presumed syncope [21].
The adverse outcomes within 10 days of initial presentation with
syncope were assessed. The statistically signiﬁcant risk factors
predictive of adverse outcomes were:
1) Age >65 years.
2) Male gender.
3) Structural heart disease.
4) Heart failure.
5) Trauma.
6) Absence of symptoms of impending syncope.
7) Abnormal ECG.
The study, however, had a low positive predictive value of only
11–14% due to a low rate of adverse events.
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The above-mentioned studies tried to identify the risk factors
hat predicted the likelihood of an adverse outcome. The risk factors
dentiﬁed in these studies tended to have a high sensitivity but
ot speciﬁcity. However, to identify the high-risk patients who  will
eed prompt hospitalization upon initial evaluation, the knowledge
rom these studies can be summarized as follows.
igh-risk markers of short-term adverse outcomes
The following risk factors were noted to be consistently asso-
iated with increased risk of adverse outcomes in all the studies
nd when identiﬁed as part of the initial evaluation almost always
esult in hospitalization of the patient.
) ACS or symptoms suggestive of ACS associated with syncope i.e.
chest pain or shortness of breath.
) Evidence of CHF at the time of presentation or a history of it.
) History of structural heart disease.
) Abnormal ECG.
) Anemia.
) Hemodynamic instability.
The ESC guidelines on management of syncope listed the criteria
or hospitalization of patients presenting with syncope. Hospital-
zation of patients is a decision that should be made carefully as one
hould be mindful of not only patient inconvenience and anxiety
ut also a high level of avoidable healthcare expenditure.
ong-term risk
Long-term risk is deﬁned as the risk of an adverse event in one
ear or longer after initial presentation with syncope. Several stud-
es have attempted to establish the long-term risk factors; several
f these are summarized below. Table 3 summarizes the ﬁndings
rom these studies.
) Martin et al.
This prospective cohort study from the University of Pitts-
burgh consisted of two groups [22]. The ﬁrst group included
252 patients with syncope who were made a part of a risk-
assessment scheme (derivation cohort). In this group, the data
from the patient’s history, physical examination, and ECG done
in the ED were used to identify predictors of arrhythmias or mor-
tality within the ﬁrst year. The second group consisted of 374
patients with syncope in order to validate the system (validation
cohort). The objective was to identify the predictors of adverse
outcomes (death or serious arrhythmias) at 1-year follow-up.
Four multivariate risk factors were identiﬁed in this study:
1) Abnormal ECG [odds ratio (OR) 3.2, 1.6–6.4] deﬁned as
rhythm abnormalities, conduction disorders, hypertrophy,
old myocardial infarction, or atrioventricular block.
2) History of ventricular arrhythmia (OR 4.8, 1.7–13.9).
3) History of congestive heart failure (OR 3.1, 1.3–7.4).
4) Age >45 years (OR 3.2, 1.3–8.1).
able 3
onger-term.
Study Clinical markers
Martin et al. [22] Abnormal ECG, CHF, SOB, ventricular arrhythmia, age
>45  years
OESIL score [23] Abnormal ECG, age >65 years, history of cardiovascular
disease, no warning
EGSYS [24] Palpitation before event, abnormal ECG or heart
disease, syncope during effort, syncope supine
CG, echocardiography; CHF, congestive heart failure; SOB, shortness of breath.diology 63 (2014) 171–177 175
In patients without any risk factors, adverse events which are
deﬁned as death or arrhythmias occurred in 7.3% of patients
in the derivation cohort and 4.4% in the validation cohort. In
patients with three to four risk factors, the above-mentioned
adverse events occurred in 80.4% of patients in the derivation
cohort and 57.6% in the validation cohort.
2) STePS study
A total of 676 patients were included in this study [21]. Long-
term adverse outcomes were deﬁned as death or the need for
major therapeutic procedures. Adverse outcomes occurred in
9.3% of the study population which included 40 (6%) deaths and
22 patients requiring major therapeutic procedures.
Five risk factors identiﬁed through a multivariate analysis
were associated with adverse outcomes in this study, which
included:
1) Age >65 years.
2) History of neoplasm.
3) Cerebrovascular disease.
4) Structural heart disease.
5) Ventricular arrhythmia.
Mortality was  noted to be higher (p < 0.05) at 1 year in patients
who  were admitted to the hospital (14.7%) compared to the
patients who were discharged (1.8%).
3) OESIL study
The risk factors identiﬁed to be predictive of 1-year mortality
in this study [23] included:
1) Age >65 years.
2) History of cardiovascular disease.
3) Lack of prodromes.
4) Abnormal ECG deﬁned as rhythm abnormalities, conduction
disorders, hypertrophy, old myocardial infarction, possible
acute ischemia, or atrioventricular block.
One-year mortality in this study increased progressively from
0% in patients with none of the above-mentioned risk factors, to
approximately 57% in patients with 4 risk factors.
4) EGSYS score
The six risk factors identiﬁed in the EGSYS study that were
predictive of adverse outcomes [24] are:
1) History or evidence of ischemic heart disease.
2) Valvular heart disease.
3) Cardiomyopathy.
4) Congenital heart disease.
5) CHF.
6) Abnormal ECG (sinus bradycardia, atrioventricular block
greater than ﬁrst degree, bundle branch block, acute or old
myocardial infarction, supraventricular or ventricular tachy-
cardia, evidence of left or right ventricular hypertrophy,
ventricular preexcitation, long QT, or Brugada pattern).
The mortality at 2 years was  noted to be 2% in patients with a
score <3 and 21% for a score >3.
Risk stratiﬁcation based on cardiac versus non-cardiac
causes of syncope
Syncope from a cardiac cause has been noted to be associated
with both short- and long-term risk of adverse outcomes. The
comparison of morbidity and mortality in patients with cardiac
syncope and non-cardiac syncope has been the subject of several
studies.
1) Soteriades et al.
A total of 7814 patients were included in this study which
evaluated the incidence and prognosis among participants in
the Framingham heart study from 1971 to 1998 [25]. Syncope
occurred in 822 patients. Cardiac cause was considered by the
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Table 4
Criteria for hospitalization or intensive evaluation based on European Society of
Cardiology 2009 guidelines.
Severe structural heart disease or coronary heart disease:
-  Heart failure
- Low left ventricular ejection fraction
-  Previous myocardial infarction
Clinical features suggestive of arrhythmic syncope:
-  Syncope in supine position
- Syncope during exertion
-  Palpitations associated with syncope
-  Family history of sudden cardiac death
Electrocardiographic ﬁndings suggesting arrhythmic syncope:
-  Nonsustained ventricular tachycardia
- Bifascicular block (left bundle branch block or right bundle branch block
combined with left anterior of posterior fascicular block)
- Other intraventricular conduction abnormalities with QRS  complex
duration >120 ms
- Inadequate sinus bradycardia (<50 bpm) or sinoatrial block in absence of
negative chronotropic medications (e.g. beta-blockers or
nondihydropyridine calcium channel blockers) or physiologic bradycardia
associated with physical training
-  Pre-excited QRS complex
-  Prolonged or short QT interval
- Right bundle branch block pattern with ST elevation in leads V1–V3
(Brugada pattern)
-  Negative T waves in right precordial leads, epsilon waves and ventricular
late potentials suggestive of arrhythmogenic right ventricular dysplasia76 V.K. Puppala et al. / Journal 
investigators to be the etiology in 9.4% and vasovagal in 21.2%. In
36.6% the cause of syncope remained unknown. The multivari-
ate hazard ratios for mortality from any cause and stroke were
noted to be signiﬁcantly higher in patients with presumed car-
diac cause of syncope when compared to patients with syncope
from other causes. The study, however, had inherent weakness
of its diagnostic classiﬁcation mainly due to the limited nature
of collected clinical information.
) Kapoor et al.
This study assessed the morbidity and mortality at the end of 5
years in a total of 433 patients who presented with syncope [26].
Initial history, physical examination, ECG, and prolonged cardiac
monitoring were helpful in assigning the cause of syncope, but
only in 22% of the study population. The mortality at the end of
5 years was noted to be signiﬁcantly higher (50.5%) in patients
with cardiac cause of syncope when compared to patients with
non-cardiac or unknown cause of syncope (24.1%). In addition,
the incidence of sudden cardiac death was noted to be signiﬁ-
cantly higher (33.1%) in patients with cardiac cause of syncope
when compared to non-cardiac (4.9%) or unknown cause (8.5%).
) Ungar et al.
This recent study which included a relatively older set of
patients (age 66 + 20 years) examined the risk of cardiovascular
mortality among the patients enrolled in Evaluation of Guide-
lines in Syncope Study 2 (EGSYS 2) study [27]. A total of 380
patients were included in this study which examined both short-
term (1 month) and long-term (2 years) mortality. A total of 35
(9.2%) deaths occurred at the end of 2 years. The deaths were
signiﬁcantly higher (82%) in patients who were older and who
had cardiac risk factors, abnormal ECG or a history of structural
heart disease and sustained injuries related to syncope when
compared to patients without abnormal ECG or structural heart
disease (3%).
) Numeroso et al.
In this recent study a total of 200 patients presenting with syn-
cope were followed to evaluate incidence of both short-term
(1 month) and long-term (1 year) adverse events which were
deﬁned as death, recurrence of syncope, cardiovascular events,
and major procedures [28]. Cardiac syncope was associated with
both greater short- and long-term occurrence of at least one
adverse event.
s syncope a marker of increased risk of cardiovascular
orbidity and mortality?
This important question remains unresolved. A large recent
opulation-based study from Denmark [29] suggested that the
ccurrence of syncope in patients without any prior history of
o-morbidities may  confer an increased risk of cardiovascular mor-
idity and mortality. A total of 37,017 (median age 47 years)
atients admitted to hospital with a ﬁrst syncope event between
001 and 2009 were identiﬁed from nationwide registries and
pproximately ﬁve times the number (n = 185,085) were chosen
rom the Danish population as control subjects (without syncope)
ho were matched for age and sex. Multivariable Cox regression
nalysis demonstrated a signiﬁcantly higher all-cause mortality
nd cardiovascular hospitalization and event rate (recurrent syn-
ope, stroke, and placement of ICD or pacemaker) in patients with
yncope when compared to the control subjects without syncope.
he study did have a major limitation in that the study popula-
ion was hospitalized patients with syncope and the other causes
ecessitating hospitalization were not controlled. The ﬁndings in
his study however do emphasize the importance of careful initial
valuation of all patients with syncope and the need for diligent
isk stratiﬁcation.Important co-morbidities:
- Severe anemia
- Electrolyte abnormalities
Conclusion
Understanding the various causes of syncope and differentiat-
ing syncope from other causes of TLOC are critical elements in the
assessment of patients who  present with ‘collapse’. In addition,
risk stratiﬁcation is an indispensable part of the initial evaluation
of patients presenting with syncope as it provides an opportunity
to identify and protect the patients at immediate risk of life-
threatening events by prompt hospitalization. Risk stratiﬁcation,
when optimal, also offers the opportunity to avoid unnecessary
hospitalization of low-risk patients, thereby reducing the health-
care expenditure. Consequently, the need to develop optimal risk
assessment tools and train front-line providers in their use cannot
be over-emphasized.
At the present time, while a consensus risk-stratiﬁcation instru-
ment remains in evolution, short-term risk stratiﬁcation studies
provide compelling evidence to hospitalize syncope patients with
a suspected cardiac cause (structural or arrhythmic). All the
long-term studies unequivocally emphasize the need for careful
evaluation and management of underlying heart disease in these
patients.
Currently, the 2009 ESC Task Force Guidelines for management
of syncope provide a useful and relatively up-to-date summary of
current criteria for hospitalization [1] (Table 4). These guidelines
strongly encourage the development within major medical cen-
ters of dedicated ‘syncope clinics,’ staffed by a multidisciplinary
team of interested medical professionals (cardiology, neurology,
internal medicine, psychiatry). Such units may  act as a resource for
accelerating effective assessment of in-hospital patients, but even
more importantly provide a readily accessible site for timely outpa-
tient evaluations of syncope/collapse patients who  did not require
urgent hospitalization.
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